The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation - PubMed (original) (raw)

Preclinical proof of principle for orally delivered Th17 antagonist miniproteins.

Berger S, Seeger F, Yu TY, Aydin M, Yang H, Rosenblum D, Guenin-Macé L, Glassman C, Arguinchona L, Sniezek C, Blackstone A, Carter L, Ravichandran R, Ahlrichs M, Murphy M, Pultz IS, Kang A, Bera AK, Stewart L, Garcia KC, Naik S, Spangler JB, Beigel F, Siebeck M, Gropp R, Baker D. Berger S, et al. Cell. 2024 Aug 8;187(16):4305-4317.e18. doi: 10.1016/j.cell.2024.05.052. Epub 2024 Jun 26. Cell. 2024. PMID: 38936360